Johnson & Johnson
Johnson & Johnson Reports Strong Q2 2026 Results and Raises Outlook
Summary
Johnson & Johnson reported a 6.6% increase in Q2 2026 sales to $25.3 billion, with adjusted operational growth of 5.7%. The company also raised its 2026 outlook, with estimated reported sales now at $101.1 billion and adjusted EPS guidance increased by $0.13 to $11.68. Notable product launches and regulatory approvals include TREMFYA for psoriatic arthritis, CAPLYTA for schizophrenia, and the Dual Energy THERMOCOOL SMARTTOUCH SF platform. The company also announced significant innovation in cancer treatments and multiple myeloma therapies.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement